Published 28 April 2009, doi:10.1136/bmj.b1714
Cite this as: BMJ 2009;338:b1714

News

Merck disguised "marketing publication" as medical journal to help promote Vioxx, court hears

¹ Byron Bay, Australia

The first 150 words of the full text of this article appear below.

The Federal Court in Australia has heard allegations that the drug company Merck produced an entire medical journal as part of its marketing campaign to allay safety fears about Vioxx (rofecoxib), its cyclo-oxygenase-2 inhibitor, which was withdrawn in 2004.

The allegations came during testimony from George Jelinek, an emergency doctor and journal editor. Dr Jelinek was called as an expert witness by lawyers acting for Graeme Peterson, who had a heart attack in 2003 after taking rofecoxib for several years and is lead plaintiff in a class action.

Strongly defending the action, Merck’s position is that the drug didn’t cause the heart attack, and the company will present evidence showing it acted responsibly. Although Merck has paid almost $5bn (£3.4bn; 3.8bn) to settle US cases related to rofecoxib, it has not admitted causation, fault, or liability.

Dr Jelinek gave evidence that the Australasian Journal of Bone and Joint Medicine, . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Merck defends Vioxx in court, as publisher apologises for fake journal

Ray Moynihan
BMJ 2009 338: b1914. [Extract] [Full Text]

Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx

Ray Moynihan
BMJ 2009 338: b1432. [Extract] [Full Text]

Online poll

Find out more on doc2doc >>